Evaxion Biotech A/S Sponsored ADR - Buy
Zacks' proprietary data indicates that Evaxion Biotech A/S Sponsored ADR is currently rated as a Zacks Rank 2 and we are expecting an above average return from the EVAX shares relative to the market in the next few months. In addition, Evaxion Biotech A/S Sponsored ADR has a VGM Score of C (this is a weighted average of the individual Style Scores which allow you to focus on the stocks that best fit your personal trading style). Valuation metrics show that Evaxion Biotech A/S Sponsored ADR may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors. The financial health and growth prospects of EVAX, demonstrate its potential to underperform the market. It currently has a Growth Score of B. Recent price changes and earnings estimate revisions indicate this would be a good stock for momentum investors with a Momentum Score of A.
Style Scorecard
Value Scorecard
Growth Scorecard
Momentum Scorecard
Value Score | EVAX: F | Industry [X] | ALLO: F | ANIX: F | ANRO: F |
---|---|---|---|---|---|
Zacks Rank | 2 | 3 | 2 | 3 | |
VGM Score | C | F | F | F | |
Cash/Price | 0.31 | 0.44 | 0.67 | 0.26 | 0.55 |
EV/EBITDA | -1.10 | -1.10 | -0.60 | -6.62 | -5.16 |
PEG Ratio | NA | 2.26 | NA | NA | NA |
Price/Book (P/B) | NA | 2.16 | 1.02 | 3.91 | 1.94 |
Price/Cash Flow (P/CF) | NA | 16.71 | NA | NA | NA |
P/E (F1) | NA | 24.76 | NA | NA | NA |
Price/Sales (P/S) | NA | 6.56 | 4,437.23 | NA | NA |
Earnings Yield | -3.03% | -27.13% | -54.35% | -15.52% | -20.99% |
Debt/Equity | -2.20 | 0.00 | 0.00 | 0.00 | 0.05 |
Cash Flow ($/share) | -5.31 | -1.53 | -1.82 | -0.31 | NA |
Growth Score | EVAX: B | Industry [X] | ALLO: D | ANIX: D | ANRO: D |
---|---|---|---|---|---|
Zacks Rank | 2 | 3 | 2 | 3 | |
VGM Score | C | F | F | F | |
Hist. EPS Growth | NA | 2.51% | NA% | NA% | NA% |
Proj. EPS Growth | 88.27% | 19.19% | 25.62% | -34.38% | 69.94% |
Curr. Cash Flow Growth | -4.81% | -2.92% | -2.79% | -27.95% | 31.29% |
Hist. Cash Flow Growth | NA | 2.50% | -17.39% | 5.35% | NA% |
Current Ratio | 1.18 | 4.63 | 12.80 | 14.40 | 26.02 |
Debt/Capital | NA | 0.00% | 0.00% | 0.00% | 4.36% |
Net Margin | NA | -220.28% | -223,139.98% | NA% | NA% |
Return on Equity | NA | -61.83% | -50.81% | -49.27% | NA% |
Sales/Assets | NA | 0.22 | 0.00 | NA | NA |
Proj. Sales Growth (F1/F0) | 19,080.71% | 1.36% | 1,151.64% | 0.00% | NA% |
Momentum Score | EVAX: A | Industry [X] | ALLO: C | ANIX: F | ANRO: D |
---|---|---|---|---|---|
Zacks Rank | 2 | 3 | 2 | 3 | |
VGM Score | C | F | F | F | |
Daily Price Chg | 3.12% | 0.93% | 2.99% | 10.36% | 4.18% |
1 Week Price Chg | 2.80% | 7.48% | 30.19% | 20.96% | 19.62% |
4 Week Price Chg | 6.45% | 0.72% | 17.45% | 6.13% | 16.04% |
12 Week Price Chg | -23.43% | -1.58% | -20.46% | -11.22% | 7.72% |
52 Week Price Chg | -73.81% | -27.04% | -44.36% | -23.90% | NA% |
20 Day Average Volume | 79,520 | 214,396 | 2,973,139 | 53,648 | 169,379 |
(F1) EPS Est. Wkly Chg | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
(F1) EPS Est. Mthly Chg | 0.00% | 0.00% | 0.33% | 0.00% | 0.00% |
(F1) EPS Est. Qtrly Chg | 48.65% | 1.06% | 9.44% | 2.27% | -42.86% |
(Q1) EPS Est. Mthly Chg | NA | 0.00% | 1.00% | 0.00% | 0.00% |
Zacks News for EVAX
Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data
EVAX: What are Zacks experts saying now?
Zacks Private Portfolio Services